

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Please cancel claim 11 without prejudice or disclaimer thereof.

Claim 1 (Currently amended): A method for determining the concentration of thrombin inhibitors in a non-turbid body liquid or a non-turbid extract from a body liquid, comprising the following steps:

- a) the body liquid is taken from a living body, and the body liquid is subjected to a separation from the turbid matter, if necessary,
- b) to the non-turbid body liquid obtained in step a) are added a coagulation-inhibiting substance not interfering in the transformation of prothrombin/ into active meizothrombin or ~~Mtdesfgl- resp. meizothrombin-des fragment 1~~, a chromogenic or fluorogenic substrate not dissociable by active meizothrombin or ~~Mtdesfgl- resp. meizothrombin-des fragment 1~~, and a substance dissociating prothrombin into meizothrombin or ~~Mtdesfgl- resp. meizothrombin-des fragment 1~~, and as an option prothrombin,
- c) the solution or mixture, ~~resp.~~, obtained in step b) is subjected to a wavelength-selective light absorption or light emission measurement as a function of the time,
- d) from the reduction of the light absorption or light emission in step c) per time unit is determined the amount of the thrombin inhibitor included in the body liquid by comparison to previously determined standard curves.

Claim 2 (Currently amended): A method for determining the activity of thrombin inhibitors in a non-turbid aqueous liquid, comprising the following steps:

- a) a body liquid is taken from a living body, and the body liquid is subjected to a separation from the turbid matter, if necessary, or a non-turbid liquid is synthetically produced,



b) to the non-turbid body liquid obtained in step a) are added a given amount of thrombin inhibitor, if applicable a coagulation-inhibiting substance not interfering in the transformation of prothrombin/ into active meizothrombin or ~~Mt desfgl resp. meizothrombin-des fragment 1~~, a chromogenic or fluorogenic substrate not dissociable by active meizothrombin or ~~Mt desfgl resp. meizothrombin-des fragment 1~~, and a substance dissociating prothrombin into meizothrombin or ~~Mt desfgl resp. meizothrombin-des fragment 1~~, or meizothrombin or ~~Mt desfgl resp. meizothrombin-des fragment 1~~, and as an option prothrombin,

c) the solution or mixture, ~~resp.~~, obtained in step b) is subjected a wavelength-selective light absorption or light emission measurement as a function of the time,

d) from the reduction of the light absorption or light emission in step c) per time unit is determined the activity of the thrombin inhibitor by comparison to previously determined standard curves.

Claim 3 (Currently amended) A method according to claim 1, wherein the coagulation inhibiting substance not interfering in the transformation prothrombin/active meizothrombin or ~~Mt desfgl resp. meizothrombin-des fragment 1~~, is selected from the group "calcium-complex forming agents, heparin, heparinoids, anti-thrombin III, protein C, fibrin polymerization inhibiting substances and mixtures of such substances".

Claim 4. (Currently amended) A method according to claim 1, wherein the substance dissociating prothrombin into meizothrombin or ~~Mt desfgl resp. meizothrombin-des fragment 1~~, is selected from the group of the snake venoms or snake venom fractions.



Claim 5. (Currently amended) A method according to claim 1, wherein the substance dissociating prothrombin into meizothrombin or ~~Mt desfgl~~ resp. meizothrombin-des fragment 1, is ecarin.

Claim 6 (Currently amended) A method according to claim 1, wherein the chromogenic substrate dissociable by active meizothrombin or ~~Mt desfgl~~ resp. meizothrombin-des fragment 1, releases p-nitroanilin under dissociation, and the light absorption measurement is performed at 405 nm.

Claim 7 (Currently amended) A method according to claim 1, wherein in step c) a first absorption or emission measurement after 0 - 100 s, preferably 0 - 50, most preferably 5 - 15 s, and a second one after another 10 - 1,000 s, preferably 50 - 500s, most preferably 150 - 300 s, measured from the addition of the substance dissociating prothrombin into meizothrombin or ~~Mt desfgl~~ resp. meizothrombin-des fragment 1, are performed.

Claim 8 (Previously presented) A method according to claim 1, wherein the thrombin inhibitor is hirudin, a hirulog or a synthetic thrombin inhibitor.

Claim 9 (Currently amended) A single test kit package for determining the concentration of thrombin inhibitors in a non-turbid body liquid or a non-turbid extract from a body liquid, comprising the following components: K1) a solution of a coagulation-inhibiting substance not interfering in the transformation of prothrombin/ into active meizothrombin or ~~Mt desfgl~~ resp. meizothrombin-des fragment 1, K2) a chromogenic or fluorogenic substrate dissociable by active



~~meizothrombin or Mtdesfgl, resp.,~~ meizothrombin-des fragment 1 and K3) a solution of a substance dissociating prothrombin into meizothrombin or ~~Mtdesfgl, resp.,~~ meizothrombin-des fragment 1 ~~wherein component K3) may be replaced or complemented by a component K3a) of a solution with meizothrombin or Mtdesfgl, resp.~~

Claim 10 (Currently amended) A single test kit package for determining the activity of thrombin inhibitors in a non-turbid body or in a non-turbid extract from a body liquid or in a non-turbid non-natural aqueous liquid, comprising the following kit components: ~~as an option K1) a solution of a coagulation inhibiting substance not interfering in a transformation~~ ~~prothrombin/active meizothrombin or Mtdesfgl, resp., K2)~~ K1) a chromogenic or fluorogenic substrate dissociable by active meizothrombin or ~~Mtdesfgl, resp.,~~ meizothrombin-des fragment 1 and ~~K3)~~ K2) a solution of a substrate dissociating prothrombin into meizothrombin or ~~Mtdesfgl, resp.,~~ meizothrombin-des fragment 1; ~~or wherein component K3) may be replaced or complemented by a component K3a) of a solution with meizothrombin or Mtdesfgl, resp.~~ meizothrombin-des fragment 1.

Claim 11. (Cancelled)

Claim 12. (Currently amended) A test kit according to claim 9, ~~wherein as an optional additional kit component,~~ further comprising a solution with prothrombin is provided.



Claim 13. (Previously presented) Thrombin inhibitors, which are available by the following steps:

A) elements of a group of prospective thrombin inhibitors are submitted subsequently or separately and simultaneously in a given and preferably identical concentration to a method according to claim 2,

B) the reduction of the light absorption or light emission per time unit is determined for each prospective thrombin inhibitor and compared to the light absorption or light emission per time unit of a given, preferably identical concentration of hirudin determined under identical conditions,

C) those prospective thrombin inhibitors are selected the reduction of the light absorption or light emission of which per time unit corresponds to at least 10 % of the corresponding reduction when hirudin is used.

Claim 14 (New): A kit package of claim 9, further comprising a standard curve for determining the amount of a thrombin inhibitor in a sample.

Claim 15 (New): A kit package of claim 9, further comprising meizothrombin or meizothrombin-des fragment 1.

Claim 16 (New): A kit package of claim 10, further comprising a standard curve for determining the amount of a thrombin inhibitor in a sample.

Claim 17 (New): A single test kit package for determining the concentration of thrombin inhibitors I a non-turbid body liquid or a non-turbid extract from a body liquid, comprising the following components: K1) a solution of a coagulation-inhibiting substance not interfering in the transformation of prothrombin into active meizothrombin or meizothrombin-des fragment 1, K2)



a chromogenic or fluorogenic substrate dissociable by active meizothrombin or meizothrombin-des fragment 1, and K3) a solution comprising meizothrombin or meizothrombin-des fragment 1.

Claim 18 (New): A kit package of claim 17, further comprising a standard curve for determining the amount of a thrombin inhibitor in a sample.